{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T16:42:45Z","timestamp":1755794565537,"version":"3.44.0"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,8,15]]},"DOI":"10.2169\/internalmedicine.4770-24","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T17:11:39Z","timestamp":1738948299000},"page":"2425-2432","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Variables That Predict Liver-related Events in Steatotic Liver Disease Diagnosed by a Liver Biopsy"],"prefix":"10.2169","volume":"64","author":[{"given":"Shinnosuke","family":"Okubo","sequence":"first","affiliation":[{"name":"Department of Medical Technology, Graduate School of Health Sciences, Okayama University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinobu","family":"Takaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikumi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Medical Technology, Graduate School of Health Sciences, Okayama University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuto","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Sue","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomi","family":"Miyake","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Onishi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Hirohata","sequence":"additional","affiliation":[{"name":"Department of Medical Technology, Graduate School of Health Sciences, Okayama University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoyuki","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Abdelhameed F, Kite C, Lagojda L, et al. Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic dysfunction-associated steatotic liver disease (MASLD): a comprehensive review from NAFLD to MAFLD and MASLD. Curr Obes Rep 13: 510-531, 2024.","DOI":"10.1007\/s13679-024-00574-z"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Rinella ME, Lazarus JV, Ratziu V, et al.; the NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78: 1966-1986, 2023.","DOI":"10.1097\/HEP.0000000000000520"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ciardullo S, Carbone M, Invernizzi P, Perseghin G. Exploring the landscape of steatotic liver disease in the general US population. Liver Int 43: 2425-12433, 2023.","DOI":"10.1111\/liv.15695"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Yang A, Zhu X, Zhang L, Ding Y. Transitioning from NAFLD to MAFLD and MASLD: consistent prevalence and risk factors in a Chinese cohort. J Hepatol 80: e154-e155, 2024.","DOI":"10.1016\/j.jhep.2023.09.033"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sookoian S, Pirola CJ. Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 47: 16-25, 2018.","DOI":"10.1111\/apt.14401"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Souza M, Diaz I, Al-Sharif L. Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals. Hepatol Int 18: 1396-1415, 2024.","DOI":"10.1007\/s12072-024-10716-z"},{"key":"7","unstructured":"7. Fujii H, Iwaki M, Hayashi H, et al.; the Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: a multicenter registry-based cohort study. Clin Gastroenterol Hepatol 21: 370-379, 2023."},{"key":"8","unstructured":"8. Serra-Burriel M, Juanola A, Serra-Burriel F, et al.; the LiverScreen Consortium Investigators. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study. Lancet 402: 988-996, 2023."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Boccatonda A, Del Cane L, Marola L, et al. Platelet, antiplatelet therapy and metabolic dysfunction-associated steatotic liver disease: a narrative review. Life (Basel) 14: 473, 2024.","DOI":"10.3390\/life14040473"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Nakano M, Kawaguchi M, Kawaguchi T, Yoshiji H. Profiles associated with significant hepatic fibrosis consisting of alanine aminotransferase &gt;30 U\/L, exercise habits, and metabolic dysfunction-associated steatotic liver disease. Hepatol Res 54: 655-666, 2024.","DOI":"10.1111\/hepr.14020"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tuo S, Yeo YH, Chang R, et al. Prevalence of and associated factors for sarcopenia in patients with liver cirrhosis: a systematic review and meta-analysis. Clin Nutr 43: 84-94, 2024.","DOI":"10.1016\/j.clnu.2023.11.008"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Njei B, Al-Ajlouni Y, Ugewndum D, Abdu M, Forjindam A, Mohamed M. Genetic and epigenetic determinants of non-alcoholic fatty liver disease (NAFLD) in lean individuals: a systematic review. Transl Gastroenterol Hepatol 9: 2024.","DOI":"10.21037\/tgh-23-31"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Chatterjee A, Basu A, Das K, Chowdhury A, Basu P. Exome-wide scan identifies significant association of rs4788084 in <i>IL27<\/i> promoter with increase in hepatic fat content among Indians. Gene 775: 145431, 2021.","DOI":"10.1016\/j.gene.2021.145431"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ha J, Yim SY, Karagozian R. Mortality and liver-related events in lean versus non-lean nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 21: 2496-2507.e2495, 2023.","DOI":"10.1016\/j.cgh.2022.11.019"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Yoshida K, Yokota K, Kutsuwada Y, et al. Genome-wide association study of lean nonalcoholic fatty liver disease suggests human leukocyte antigen as a novel candidate locus. Hepatol Commun 4: 1124-1135, 2020.","DOI":"10.1002\/hep4.1529"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Shah AG, Lydecker A, Murray K, et al.; Nash Clinical Research Network. Comparison of non-invasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 7: 1104-1112, 2009.","DOI":"10.1016\/j.cgh.2009.05.033"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yoneda M, Imajo K, Eguchi Y, et al.; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Non-invasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. J Gastroenterol 48: 1051-1060, 2013.","DOI":"10.1007\/s00535-012-0704-y"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Hsu C, Caussy C, Imajo K, et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol 17: 630-637. e8, 2019.","DOI":"10.1016\/j.cgh.2018.05.059"},{"key":"19","unstructured":"19. Vali Y, Lee J, Boursier J, et al.; the Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) consortium investigators. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol Hepatol 8: 714-725, 2023."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kawaguchi T, Murotani K, Kajiyama H, et al. Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials. J Gastroenterol 59: 836-848, 2024.","DOI":"10.1007\/s00535-024-02122-x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kawaguchi T, Fujishima Y, Wakasugi D, et al. Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan. J Gastroenterol 59: 1120-1132, 2024.","DOI":"10.1007\/s00535-024-02158-z"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/16\/64_4770-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T03:43:15Z","timestamp":1755315795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/16\/64_4770-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":21,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4770-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"article-number":"4770-24"}}